Discover PsA

Discover the Unmet Need in Psoriatic Arthritis

The journey of patients with psoriatic arthritis is all too often characterized by therapy switch, augmentation, and discontinuation–underscoring the need for new treatment options30, 31

Fold image
corner image

PsA Patients Experience Changes in Treatment Including Discontinuation, Switching, and Augmentation

A retrospective observational study of a large health insurance database identified 1,698 patients with PsA who had never taken a biologic DMARD and were new users of an oral nonbiologic DMARD in the period from 2005 to 2009.30 Overall, these patients had had an average of 10 outpatient visits during the 6 months before starting DMARD treatment.30 Of those who started taking any oral nonbiologic DMARD, 72% had 1 or more changes in therapy within 1 year: 80% of them discontinued therapy, 29% had therapy augmentation, and 32% switched therapies.30 The reasons for therapy change were not reported.

The National Psoriasis Foundation conducts biannual surveys to identify undertreatment, treatment trends, and treatment satisfaction among patients with psoriasis and psoriatic arthritis.10 From 2003 to 2011, a total of 5,604 patients in the United States responded to these surveys; among 1,712 respondents with psoriatic arthritis, 45.5% reported dissatisfaction with their treatment.10 Those who reported that they discontinued therapy named safety concerns, lack of efficacy, and lack of insurance coverage as the top reasons for discontinuation.10

Learn more about the burden of psoriatic arthritis.

Fold image
corner image

Receive Email Updates & Additional Information

Sign-up Now »
Fold image
corner image

References:

  • 10 Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States. JAMA Dermatol. doi:10.1001/jamadermatol.2013.5264.
  • 30 Zhang F, Gauthier G, Hiscock R, Curtis J. Treatment patterns in psoriatic arthritis patients newly initiated on non‑biologic disease‑modifying anti‑rheumatic drugs. Presented at the 12th Annual Meeting of the ACR/ARHP. November 10‑14, 2012; Washington, DC.
  • 31 Zhang F, Li S, Curtis JR. United States treatment patterns in psoriatic arthritis newly initiated on etanercept or adalimumab. Presented at the 15th Annual European Conference of ISPOR. November 3‑7, 2012; Berlin, Germany.
Fold image
corner image